Newswire (Published: Tuesday, April 11, 2017, Received: Friday, April 7, 2017, 7:04:44 PM CDT)

Word Count: 469

Erasmus University Medical Center Describes Findings in Prostate Cancer (Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting originating from Rotterdam, Netherlands, by NewsRx correspondents, research stated, "To estimate the increase in prostate cancer mortality (PCM) and the reduction in overtreatment resulting from different active surveillance (AS) protocols, compared with treating men immediately. We used a microsimulation model (MISCAN-Prostate), with the natural history of prostate cancer based on European Randomized Study of Screening for Prostate Cancer data."

Financial support for this research came from National Cancer Institute as part of the Cancer Intervention and Surveillance Modeling Network (CISNET) (see also Oncology - Prostate Cancer).

Our news editors obtained a quote from the research from Erasmus University Medical Center, "We estimated the probabilities of referral to radical treatment while on AS, depending on disease stage, using data from the Johns Hopkins AS cohort. We sampled 10 million men, representative of the US population, and projected the effects of applying AS protocols that differed by time between biopsies and compared these with the effects of treating men immediately. We found that AS with yearly follow-up biopsies for men with low-risk prostate cancer ( less than or equal to T2a stage and Gleason 6) increases the probability of PCM to 2.6% (1% increase) and reduces overtreatment from 2.5 to 2.1% (18.4% reduction). With biopsies every 3 years after the first year, PCM increases by 2.3% and overtreatment reduces from 2.5 to 1.9% (30.3% reduction). The inclusion of men in the intermediate-risk group (>T2a stage or Gleason 3+4) in AS protocols increases PCM by 2.7% and reduces overtreatment from 2.5 to 2.0% (23.1% reduction). These results may not apply to African-American men. Offering AS to men with low-risk prostate cancer is relatively safe."

According to the news editors, the research concluded: "Increasing the biopsy interval from yearly to up to every 3 years after the first year will significantly reduce overtreatment among men in the low-risk group, with limited PCM risk."

For more information on this research see: Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study. Bju International, 2016;119(4):560-566. (Wiley-Blackwell - www.wiley.com/; Bju International - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410X)

The news editors report that additional information may be obtained by contacting T.M. de Carvalho, Dept. of Public Health, Erasmus University Medical Center, Rotterdam, Netherlands. Additional authors for this research include E.A. Heijnsdijk and H.J de Koning.

Keywords for this news article include: Europe, Oncology, Rotterdam, Netherlands, Epidemiology, Prostate Cancer, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

National Cancer Institute

Places

Western Europe
Netherlands
Europe
Rotterdam

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research